Specificity and stability of a new PTH1 receptor antagonist, mouse TIP(7-39)

Peptides

Volumn 23, Issue 5, 2002, Pages 989-998

  Hoare, Sam R J ^a   Usdin, Ted B ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Hypercalcemia; Hyperparathyroidism; Parathyroid hormone; Plasma pharmacokinetics; Tuberoinfundibular peptide

Indexed keywords

HORMONE RECEPTOR BLOCKING AGENT; PARATHYROID HORMONE RECEPTOR; PARATHYROID HORMONE RECEPTOR BLOCKING AGENT; PARATHYROID HORMONE RELATED PROTEIN; THREONYLISOLEUCYLPROLINE[7-39]; UNCLASSIFIED DRUG; CYCLIC AMP; NEUROPEPTIDE; PEPTIDE FRAGMENT; TUBEROINFUNDIBULAR PEPTIDE 39;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG STABILITY; ENZYME INACTIVATION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RECEPTOR BLOCKING; STRAIN DIFFERENCE; VENOUS BLOOD; ANIMAL; BLOOD; CATTLE; CELL STRAIN COS1; CHEMISTRY; DRUG ANTAGONISM; GENETIC TRANSFECTION; GENETICS; HALF LIFE TIME; METABOLISM; MOUSE; RADIOASSAY; RAT; SENSITIVITY AND SPECIFICITY;

ANIMALIA; BOVINAE;

ANIMALS; CATTLE; COS CELLS; CYCLIC AMP; HALF-LIFE; HUMANS; MICE; NEUROPEPTIDES; PEPTIDE FRAGMENTS; RADIOLIGAND ASSAY; RATS; RECEPTORS, PARATHYROID HORMONE; SENSITIVITY AND SPECIFICITY; TRANSFECTION;

EID: 0036072777     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(02)00023-2     Document Type: Article

References (42)

1. Parathyroid hormone-related peptide is a potent tumor angiogenic factor
2. Use of octadecasilyl-silica for the extraction and purification of peptides in biological samples. Application to the identification of circulating metabolites of corticotropin-(1-24)-tetracosapeptide and somatostatin in vivo
3. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy
4. Parathyroid hormone-related peptide stimulates proliferation of highly tumorigenic human SV40-immortalized breast epithelial cells
5. Modifications of position 12 in parathyroid hormone and parathyroid hormone related protein: Toward the design of highly potent antagonists
6. Multiple regions of ligand discrimination revealed by analysis of chimeric parathyroid hormone 2 (PTH2) and PTH/PTH-related peptide (PTHrP) receptors
7. Inhibition of the in vivo parathyroid hormone-mediated calcemic response in rats by a synthetic hormone antagonist
8. 2
9. NPS R-568: A type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium
10. Regions in rat and human parathyroid hormone (PTH) 2 receptors controlling receptor interaction with PTH and with antagonist ligands
11. Parathyroid hormone-related protein (PTHrP) and hypercalcaemia
12. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo
13. Measurement of agonist and antagonist ligand-binding parameters at the human parathyroid hormone type 1 receptor: Evaluation of receptor states and modulation by guanine nucleotide
14. Molecular determinants of tuberoinfundibular peptide of 39 residues (TIP39) selectivity for the parathyroid hormone-2 (PTH2) receptor. N-terminal truncation of TIP39 reverses PTH2 receptor/PTH1 receptor binding selectivity
15. Tuberoinfundibular peptide (7-39) [TIP(7-39)], a novel, selective, high-affinity antagonist for the parathyroid hormone-1 receptor with no detectable agonist activity
16. Quantitative cell membrane-based radioligand binding assays for parathyroid hormone receptors
17. A parathyroid hormone inhibitor in vivo: Design and biological evaluation of a hormone analog
18. Evaluation of a parathyroid hormone antagonist in an in vivo multiparameter bioassay
19. Tuberoinfundibular peptide 39 binds to the parathyroid hormone (PTH)/PTH-related peptide receptor, but functions as an antagonist
20. The extracellular amino-terminal region of the parathyroid hormone (PTH)/PTH-related peptide receptor determines the binding affinity for carboxyl-terminal fragments of PTH-(1-34)
21. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-releated peptide
22. Inactivation by plasma may be responsible for lack of efficacy of parathyroid hormone antagonists in hypercalcemia of malignancy
23. Nuclear and nucleolar localization of parathyroid hormone-related protein
24. Inhibition of processing of parathyroid hormone-related peptide by anti-sense furin: Effect in vitro and in vivo on rat Leydig (H-500) tumor cells
25. The 7-34-fragment of human hypercalcemia factor is a partial agonist/antagonist for parathyroid hormone-stimulated cAMP production
26. Calcimimetic compounds: A direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism
27. Parathyroid hormone-related protein as a potential target of therapy for cancer-associated morbidity
28. Structure of tuberoinfundibular peptide of 39 residues
29. Parathyroid hormone: Physiology, chemistry, biosynthesis, secretion, metabolism and mode of action
30. Regulation in vivo of the growth of Leydig cell tumors by antisense ribonucleic acid for parathyroid hormone-related peptide
31. Mechanisms of action of bisphosphonates
32. The effect of PTH antagonist BIM-44002 on serum calcium and PTH levels in hypercalcemic hyperparathyroid patients
33. Passive immunization with anti-parathyroid hormone-related protein monoclonal antibody markedly prolongs survival time of hypercalcemic nude mice bearing transplanted human PTHrP-producing tumors
34. Distribution and pharmacokinetics of a potent peptide antagonist of parathyroid hormone and parathyroid hormone-related protein in the rat
35. Identical complementary deoxyribonucleic acids encode a human renal and bone parathyroid hormone (PTH)/PTH-related peptide receptor
36. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism
37. Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The hypercalcemia study group
38. The physiology of parathyroid hormone-related protein
39. Medical approaches to primary hyperparathyroidism
40. Evidence for a parathyroid hormone-2 receptor selective ligand in the hypothalamus
41. TIP39: A new neuropeptide and PTH2-receptor agonist from hypothalamus
42. The PTH2 receptor and TIP39: A new peptide-receptor system